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Recombinant Measles Virus Induces Cytolysis of
Cutaneous T-Cell Lymphoma In Vitro and In Vivo
Valerie Ku¨nzi1,3, Patrick A. Oberholzer2,3, Lucie Heinzerling2,4, Reinhard Dummer2 and Hussein Y. Naim1
Measles virus (MV) has shown promise as an oncolytic virus in the treatment of different tumor models for
human B-cell lymphoma, multiple myeloma, ovarian cancer, and glioma. We have shown that, in a phase I
clinical trial, MV vaccine induces tumor regression in cutaneous T-cell lymphoma (CTCL) patients. Here, we
investigated in detail, the effect of recombinant MV (rMV) vaccine strain in CTCL cell cultures, and in vivo in
established CTCL xenografts in nude mice. The susceptibility of three CTCL cell lines, originating from patients,
to rMV was tested by determination of cell surface expression of MV receptors. All cell lines expressed the
receptors CD150 and CD46 and were easily infected by rMV and induced complete cell lysis. The cytoreductive
activity was apparent in cells forming aggregates, indicating a cell-to-cell spread of MV and cytolysis owing to
virus infection. Intratumoral (i.t.) injection of rMV, expressing enhanced green fluorescent protein induced
complete regression of large established human CTCL tumors in nude mice, whereas tumors with control
treatment progressed exponentially. Immunohistochemical analysis of tumor biopsies, after i.t. treatment, for
MV–NP protein complex demonstrated replication of MV within the tumors. The data demonstrate the potential
of MV as a therapeutic agent against CTCL.
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INTRODUCTION
Cutaneous T-cell lymphomas (CTCLs) are the second most
common extranodal lymphomas and are characterized by a
clonal proliferation of neoplastic T-lymphocytes. Owing to
expression of homing factors, such as the cutaneous lympho-
cyte antigen and chemokine receptor (e.g. CXCR) (Rook and
Heald, 1995), early clinical stages are present in the epidermis,
with infiltrates particularly along basal layer and adjacent to
Langerhans cells. However, as disease progresses, neoplastic
cells are detected within dermal infiltrates in increasing
numbers, at time sentailed with loss of epidermotropism.
Although patients with limited patch/plaque disease of less
than 10% of the body surface area (T1) have a normal life
expectancy, patients who undergo transformation to large-cell
lymphoma (8–23% of patients) have a poor prognosis with a
mean survival of 2–19 months (Saxon, 2000).
There are various therapeutic modalities that show activity
in CTCL (Kim et al., 2005). Treatments frequently applied for
skin manifestations include surgical excision of solitary
lesions, high potency topical corticosteroids, PUVA (psoralen
und UVA), or locally applied cytostatics such as topical
carmustine (Zackheim et al., 1990) or radiation therapy
(Dummer et al., 1996). However, the curative potential of
skin-directed treatments is considerably pessimistic because
neoplastic T-lymphocytes readily circulate (Vonderheid,
2002).
As clonal CD4þ tumor cell populations in CTCL show a
defect in the IFN signal transduction pathway (Sun et al.,
1998; Dummer et al., 2001; Willers et al., 2001), they can be
selectively targeted by IFN-sensitive viruses such as vesicular
stomatitis virus or measles virus (MV) in vitro and in vivo in
the presence of IFN-a (Heinzerling et al., 2005). In fact,
beneficial effects of viral infections on lymphoma patients
have been known for decades. It is assumed that mechanisms
underlying so-called ‘‘spontaneous’’ tumor regressions in
Hodgkin’s disease (Zygiert, 1971; Mota, 1973; Taqi et al.,
1981) and Burkitt’s lymphoma (Bluming and Ziegler, 1971;
Ziegler, 1976) after measles infection are due to viral
oncolysis and/or virus-induced anti-tumor immune responses.
This assumption is supported by studies using replication-
competent attenuated MV Edmonston B vaccine strain
in animal models to treat various types of cancer such as
human B-cell lymphoma (Grote et al., 2001), multiple
myeloma, ovarian cancer, and glioma xenografts inducing
tumor regression after intratumoral (i.t.), intraperitoneal (i.p.),
and intravenous administration (Peng et al., 2001, 2002;
Phuong et al., 2003). In addition, the ability of MV to induce
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anti-neoplastic activity causing tumor regression in CTCL
patients has recently been demonstrated (Heinzerling et al.,
2005), accompanied by an excellent safety and toxicity profile.
MV is an enveloped negative strand RNA virus and
belongs to the Paramyxoviridae family, genus Morbilli virus.
Its genome encodes six viral proteins, the nucleoprotein (N),
the phosphoprotein (P), the viral polymerase (L), the matrix
protein (M), and the two surface glycoproteins, hemaggluti-
nin (H) and fusion protein (F). Glycoproteins H and F mediate
virus-to-host cell attachment and fusion, respectively. More-
over, F and H glycoproteins on surfaces of infected cells
mediate fusion with neighboring uninfected cells leading
to spread of infection (Goodbourn et al., 2000; Naniche
et al., 2000).
The receptors of MV are well defined. Currently, two
natural receptors have been identified, differing in their
predominant interaction with the wild-type or the live
attenuated vaccine strains. Whereas wild-type MV strain
binds mainly to CD150, a signaling lymphocytic activation
molecule (Ogata et al., 2004), the live attenuated vaccine
strains interact predominantly with CD46, a member of the
regulators of complement activation gene cluster with wide
distribution on all human-nucleated cells (Naniche et al.,
1993; Dorig et al., 1994). Expression of CD46 by CTCL
T-lymphocytes entailed with a defect in the IFN signaling
pathway would thus render these cells susceptible to the
MV vaccine.
In this study, we employed a recombinant measles virus
(rMV) expressing the enhanced green fluorescent protein
(eGFP) (rMeGFPV) to eliminate CTCL cells in cultures and in
a CTCL animal tumor model. We show that rMV efficiently
infects CTCL cells, spreads from cell-to-cell, and induces cell
lysis. In an animal model with CTCL tumors, MV induced
complete regression of tumor growth.
RESULTS
CTCL cells express MV receptors CD46 and CD150
To determine whether the MV vaccine receptor, CD46, is
expressed on the surface of lymphoma cells lines, flow
cytometry was performed on three patient-derived lymphoma
cell lines, MyLa2059, SeAx, and HUT78, using isotope-
matched controls. Three sets of cells in duplicates were
stained with anti-CD46 coupled to FITC. All three cell lines
were found to express the CD46 receptor on the surface of
the majority of cells: MyLa2059, 98.1%; SeAx, 96.7%; and
HUT78, 99.6% (Figure 1a). As CD150 was shown to act as a
receptor for the wild-type MV (Erlenhofer et al., 2002), and
may facilitate the interaction of the vaccine strain with
CD150-expressing cells, another set of cells was probed with
anti-CD150 coupled to FITC as described above. High
numbers of gated positive cells for this receptor were also
detected with around 60% for HUT78 cells and 76.6 and
89% for SeAx and MyLa2059, respectively (Figure 1b). These
results indicate that all three cell lines represent suitable
targets for the attenuated and wild-type strains of MV.
rMV is cytopathic in CTCL cells
As all tested lymphoma cells expressed CD46 quantitatively,
their susceptibility to MV infection was tested. The ability of
rMV to infect and lyse cultures of CTCL cells in suspension
was assessed. Equal numbers of cultured CTCLs were infected
with 0.2 plaque-forming unit (PFU)/cell of rMV (rMeGFPV)
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Figure 1. Quantification of CD46 and CD150 expression by FACS analysis. Surface expression of MV receptors by CTCL cell lines was analyzed by means of
anti-CD46 or anti-CD150 (signaling lymphocytic activation molecule) antibodies and a secondary antibody conjugated to FITC. All three lymphoma cell lines,
MyLa2059, SeAx, and HUT78, expressed (a) CD46 and (b) CD150 at relatively high levels. Open histograms represent staining of CD46 or CD150. Filled
histograms represent the isotype control. Numbers indicate the percentage of gated positive cells.
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and incubated at 371C. As eGFP is expressed by the MV
genome, the detection of eGFP signal (under UV or FITC
filter) is an indication for MV propagation. The onset of virus
infection was detectable in all cell lines (SeAx, HUT78, and
MyLa2059) at 24 hours post infection (Figure 2) and the
number of infected cells increased with time. Although cell
death was observed in all infected cultures after a prolonged
incubation, the kinetics of virus spread (i.e. number of
infected cells at a given time) differed between MyLa2059
and SeAx on one hand and HUT78 on the other hand.
Virus propagation was more efficient in MyLa2059 and
SeAx cells than in HUT78 cells. It has previously been shown
that MV is efficiently transmitted from cell-to-cell (Ehren-
gruber et al., 2002) if cells are in a physical contact. The
slower spread of rMV in HUT78 cells is likely due to the fact
that, in suspension, HUT78 cells do not aggregate as
effectively as MyLa2059 and SeAx cells. Moreover, virus
shedding from CTCL cells was remarkably lower compared to
shedding from fibroblast cells. The peak titers of MV in
CTCL cells did not exceed 50 PFU/ml (Figure 3c) compared
to 106 PFU/ml in fibroblast cells (Ehrengruber et al., 2002).
This finding rules out the possibility of secondary
infections by cell-free viruses shed into the medium, favoring
cell-to-cell spread of MV infection (Figure 3b, shown for
MyLa2059).
In order to simulate the tumor lysis in vivo, where 100% of
cell death is required, we determined the infectious dose
needed to fulfill this task. MyLa2059 cells were selected
because they were used as xenografts in the mouse model
(see below). Cultures of MyLa2059 cells were infected at an
increasing multiplicity of infection (MOI) with rMeGFPV and
incubated at 371C for various time periods. Cell lysis by each
infectious dose was recorded as a function of time (Figure 3).
Whereas an MOI of 0.01 or 0.1 PFU/cell was not sufficient to
infect 100% of cells at 4 days, 480% of the cells could be
infected at a longer incubation time (45 days). However,
drastic cell death was observed for MOIs of 1.0, 5.0, and
10.0 PFU/cell; starting on day 3 for MOI of 5.0 or 10.0 PFU/
cell (B100%), and after 4 days for MOI of 1.0 PFU/cell
(480%) (Figure 3a). Cell lysis occurred as a consequence of
infection, leaving a lawn of debris that was observed at 3 days
post infection (dpi) (Figure 3b, arrows). In addition, the
regression of the eGFP signal, observed at day 3, was
concomitant with cell death ‘‘or cell-lysis’’. On the other
hand, non-infected control cells grew steadily with time, and
an increased number of cell aggregates, typical for these
cells, was observed (Figure 3b).
Multiple dose administration of rMeGFPV resulted in a
similar kinetics of cell death as shown for single-dose
treatments. Taken together, the results indicate that cell
death and lysis are a consequence of MV infection and that
an MOI of 40.1 PFU/cell, in one or multiple applications,
may be sufficient to induce 480% of cell lysis.
rMV replicates lytically in CTCL cells
To further analyze whether CTCL cell lysis is a consequence
of virus replication, kinetics of viral protein expression were
analyzed at various days post rMV infection. Figure 3c shows
the kinetics of MV protein expression, represented by N, P,
and H. The peak of protein expression, and thus replication,
was measured at 2 dpi and gradually decreased at 3 dpi. The
drastic regression of MV protein concentration at 4 dpi
supports the microscopic analysis shown in Figure 3b. The
decrease in protein expression paralleled the decrease of
eGFP signal and virus shed on days 3 and 4. Lower levels of
viral proteins remained detectable up to 7 dpi, but infectivity
was not detectable after 4 days (Figure 3c). The data clearly
demonstrate that CTCL cell death is a consequence of rMV
infection and replication.
I.t. injection of rMV causes complete regression of established
CTCL xenografts
Effects of MV treatment in mice with established B-cell
lymphoma have been shown to occur at higher doses of rMV
infection (Grote et al., 2001). In addition, intralesional
injections of replicating MV vaccine has been used in a
clinical trial showing promising results in suppressing tumor
growth (Heinzerling et al., 2005). In order to investigate the
efficiency of rMV in T-cell lymphoma upon administration of
a lower dose, mice with subcutaneous MyLa2059 tumor
xenografts were injected i.t. with rMV for 3 days in series,
followed by six injections every second day using
3.0104 PFU/dose (a dose tested in cell culture). Another
group of mice were injected i.p. with 5.0 104 PFU/dose
following the same injection schedule. I.t. injections resulted
in tumor growth regression after the third injection. Complete
regression of tumors was observed at 15 days (Figure 4a and
SeAx
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HUT78
200m
Figure 2. Infection of T-lymphoma cell lines by rMV. Cells were infected
with rMeGFPV at an MOI of 0.2 PFU/cell. Virus replication and cell death was
visualized by microscopy (UV for GFP and phase contrast for total cell
culture). The change of cell morphology (vesiculation and disintegration) is a
typical indication of lysis as shown for SeAx and MyLa2059 cells (arrows).
Bar¼200 mm.
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b). Figure 4a shows the kinetics of tumor regression with time,
and Figure 4b shows a typical effect in the mouse model
before, during, and after treatment. Tumor re-growth was not
observed after the termination of the treatment. Mice injected
i.p. by rMV and the control mice (injected with NaCl or left
untreated) exhibited exponential tumor growth. Staining for
MV N–P complexes of treated tumors, before complete
regression, showed positive immunoreactivity to N–P proteins
(Figure 4c). Untreated control tumors were negative for N–P
(data not shown).
0
20
40
60
80
100
120
1 2 3 4
Days post infection
In
fe
ct
ed
 c
el
ls 
(%
) MOI 0.01
MOI 0.1
MOI 1.0
MOI 5.0
MOI 10.0
a
Day 1 Day 2 Day 3 Day 4 
Co
nt
ro
l
In
fe
ct
ed
-ly
se
d
b
Me
GF
PV
Ct
rl c
ell
s
7 d
pi
4 d
pi
3 d
pi
2 d
pi
1 d
pi
Virus shed
[×101] p.f.u.  
N
P
H
_ 6 32 16 6 0Ctrl
c
100m 100m 100m 100m
100m100m100m100m
100m 100m 100m 100m
Figure 3. CTCL cells are infected and lysed by rMV. (a) Determination of infectious virus dose in tumor cell culture. MyLa2059 cells were infected by
MV expressing the eGFP at MOI 0.01, 0.1, 1, 5, and 10 PFU/cell. The percentage of infected cells (in triplicates) was assessed daily by counting cells
expressing GFP, and the average of triplicates was blotted. The experiment was terminated at a 100% cell infection. (b) Time course of infection and death
of MyLa2059 cells infected with rMeGFPV at an MOI of 5 PFU/cell. Arrows indicate cellular debris and aggregates as a result of cellular burst. Control
non-infected cells are shown in the third panel. Original magnification 10. (c) MyLa2059 cells were infected with rMeGFPV at an MOI of 5 PFU/cell. On day
1–4 and on day 7, cells and medium were harvested. Virus replication within cells was analyzed by SDS–PAGE using an antibody mix directed against MV N, P,
and H. The total amount of virus shed into the medium was determined by plaque assays on Vero cells. Values are means of duplicates (Ctrl, control
non-infected cells; dpi, days post infection; pfu, plaque forming unit), bar¼ 100 mm.
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DISCUSSION
T-cell lines established from patients with CTCL (Sun et al.,
1998) and purified clonal T-lymphocytes from the blood of
Se´zary syndrome patients (Dummer et al., 2001; Willers
et al., 2001) are characterized by a defect in the IFN signaling
pathway. French et al. (2005) demonstrated a defect in the
expression of CD40 ligand (IFN ligand) on malignant T cells
derived from patients with Se´zary syndromes, which can lead
to a profound reduction in dendritic cell activation and
cytokine production. Earlier, Showe et al. (1999) showed that
Se´zary syndrome CD4þ cells had severely reduced levels of
STAT4, suggesting that they have a depressed response to any
inducer of the STAT4 signal transduction pathway including
IFN-a. These findings indicate that CTCL are prevented from
an adequate anti-viral response which makes them attractive
targets for oncolytic virotherapies (Dummer et al., 2001).
A promising candidate for viral-based cancer therapies are
attenuated measles vaccine strains. They have an excellent
safety profile and have been used in millions of children over
decades. Oncolytic activity of certain members of the
Edmonston vaccine strains against a broad spectrum of
lymphoid and non-lymphoid human cancer has already been
shown in cell culture and animal model malignancies
(Dummer et al., 2001; Grote et al., 2001; Peng et al., 2001,
2002, 2003a; Phuong et al., 2003; Dingli et al., 2004). In
addition, we recently reported the successful use of MV
Edmonston Zagreb vaccine strain in a clinical study involving
patients suffering from CTCL, demonstrating for the first time
excellent tolerability and anti-tumor response in CTCL
patients (Heinzerling et al., 2005). Successful infection of
malignant cells by MV strains was mainly mediated by
efficient virus-to-cell attachment via the major MV vaccine
receptor CD46 known to be expressed at high levels on the
surface of most human cells and tumors (Erlenhofer et al.,
2002; McQuaid and Cosby, 2002; Anderson et al., 2004).
Although MV-Edmoston B vaccines have attenuated patho-
genicity for normal human tissue, they are coincidentally
potently oncolytic against tumor cells.
In this report, we demonstrate that using a low dose
(p105 PFU) of rMV, in vitro and in vivo, is sufficient to
induce regression of CTCL tumor growth. Here, we confirm
our clinical results using a lower vaccine dose (p5104) of
MV in CTCL patients (Heinzerling et al., 2005) and suggest
that MV oncolytic activity is transmitted from cell-to-cell. We
also demonstrate that the inherent MV cytolytic activity is the
cause of CTCL cell death and tumor regression in the murine
model. Infection of three T-lymphoma cell lines (SeAx,
MyLa2059, and HUT78) in vitro by an rMV vector was
successful and led to cell lysis in a dose-dependent manner.
In the murine tumor model with human CTCL tumor grafts,
we have shown that rMV causes regression of large
established tumor xenografts in contrast to control animals
where all tumors progressed. The finding that i.p. treatment
did not result in tumor regression may be owing to the
inability of rMV to reach the tumor in a short time. The blood
network connecting the encapsulated skin tumor is physically
very distant from the peritoneal cavity. In this case, rMV may
have lost infectivity before reaching the tumor site.
This study provides additional evidence for the capacity of
an attenuated MV vaccine to lyse lymphoma tumors in vivo,
using relatively low doses of the rMV vaccine. Similar effects
have been previously observed for B-lymphoma but at
relatively higher doses (Grote et al., 2001). We presume that
different cancer cells may respond to MV infectious doses
differently, thus the therapeutic dose of MV would need to be
determined for every type of cancer.
We should mention here that virus-based treatment has to
be developed very carefully. By using intralesional therapy in
patients, who have significant humoral antibody responses
against the vectors used, the risk of systemic spread or
significant side effects is low. On the other hand, the
antibodies might significantly reduce the clinical benefit of
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Figure 4. I.t. injections of CTCL xenografts with rMV results in significant
retardation of tumor growth in nude mice. CTCL grafts in outbreed ICR nu/nu
mice were left to grow to an average size of 0.2 cm3 before start of treatment
with recombinant MV (rMeGFPV). Mice were injected with rMeGFPV i.t.
(3.0 104 PFU/dose) or i.p. (5.0104 PFU/dose) on days 1, 2, 3, 5, 7, 9, 11,
13, and 15. Control mice were injected on the same days with NaCl i.t., i.p.,
or left without treatment. (a) Significant tumor growth inhibition after i.t.
treatment (n¼ 6; rhombs) as compared to i.p. treatment (n¼ 6; squares) and
the untreated controls (n¼ 6; triangles). Means of tumor sizes in cm3 (7SD)
during the course of the treatment (arrows indicate injections). (b) Regression
of tumor grafts in nude mice during i.t. treatment shown in (a). Tumor
development was documented by photography. Typical regression of tumor
growth is shown. (c) Immunoreactivity for MV NP protein is demonstrated by
peroxidase staining. Treated tumor shows an intensively positive stained
cluster of lymphocytes in the central part. Bar¼ 50mm.
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MV-based treatment. Therefore, a specifically targeted rMVs
may have the best risk benefit ratio, for a future therapy
model.
An earlier study, pioneering the change of MV tropism
(Fehr et al., 1998; Spielhofer et al., 1998), proved the
feasibility of MV as a targeting vector. Based on these
findings, many studies reported the development of rMVs
specifically targeting tumor cells via known tumor-specific
surface proteins (Schneider et al., 2000; Hammond et al.,
2001; Bucheit et al., 2003; Peng et al., 2003b, 2004). To
enhance the anti-tumor activity of targeted viruses, they can
be armed with ‘‘payloads’’ that activate tumor death, a
fundamental technique in virotherapy (Bell et al., 2003). This
activity could be achieved by using oncolytic vectors coding
for therapeutic genes (e.g. cytokines or genes exhibiting
tumor cell killing properties) as recently shown for a related
virus (Obuchi et al., 2003).
As MV ensures efficient gene transfer, sustained expression
of therapeutic transgenes is also expected to be safe and
efficacious in humans, providing all characteristics requested
for developing a future gene delivery system. In this respect,
the potential of MV vaccine for extended clinical application
(Heinzerling et al., 2005) represents a milestone towards the
development of MV-based cancer therapy.
MATERIALS AND METHODS
Cells
Three T-lymphoma cell lines, SeAx (three passages), MyLa2059
(kindly provided by K. Kaltoft, Aahus, Denmark), and HUT78
(4 passages) (Kaltoft et al., 1987; Kaltoft et al., 1992), were incubated
in Rosewell Park Memorial Institute medium 1640 (GIBCO BRL,
Scotland, UK, Catalog No. 31870-025) supplemented with 10% heat-
inactivated fetal calf serum (GIBCO BRL, Catalog No. 10270106),
1% penicillin/streptomycin (GIBCO BRL, Catalog No. 15240-096),
2% L-glutamine (Biochrom AG, Berlin, Germany, Catalog No. K0282),
and 1% sodium pyruvate (GIBCO BRL, Catalog No. 11360-039) at
371C, 5% CO2.
MV and production
The virus used in this study was a live attenuated rMV, originally
stemming from the Edmonston B vaccine strain. cDNA clones were
modified by an additional transcription unit expressing the enhanced
green fluorescent protein (eGFP), and corresponding recombinant
viruses were rescued (named rMeGFPV) (Naim et al., 2000;
Ehrengruber et al., 2002). Virus stocks were prepared in Vero cells
as reported previously (Ehrengruber et al., 2002). Briefly, subcon-
fluent monolyers of Vero cells were infected at an MOI of 0.01 PFU/
cell, and incubated for 90 minutes at 351C. The viral inoculum was
removed and replaced by DMEM containing 5% fetal bovine serum
(GIBCO BRL). Cultures were then monitored until all cells were in
syncytia. Cell-free virus was taken, clarified by centrifugation,
aliquoted, titrated by plaque assay on Vero cells, and stored
at 801C.
Flow cytometry and immunhistochemistry
Cell lines were analyzed for the expression of CD46 (kindly provided
by Dr J. Schneider-Schaulies, Wu¨rzburg, Germany) and CD150
(signaling lymphocytic activation molecule) (BD Bioscience
PharMingen, www.bdbiosciences.com, Catalog No. 559592) com-
pared to isotype-matched mouse IgG1 FITC (Becton Dickinson, NJ,
Catalog No. 345815) and mouse IgG1 phycoerythrin (Becton
Dickinson, NJ, Catalog No. 345816) controls by FACS analyses
using a flow cytometer (FACS Calibur, Becton Dickinson). Data were
processed using CellQuestPro (Becton Dickinson). Immuno-
stainings were visualized by Alcalic Phosphatase–Antialcalic Phos-
patase Complex or PAP. A negative control without specific primary
antibody was carried out in parallel to all stainings. The detection of
MV replication in biopsies after rMV treatment was carried out on
thin sections from fixed and imbedded tumors. Thin sections were
probed with a mAb recognizing both N and P complexes (kindly
provided by F. Wild, Paris, France). An horseradish peroxidase-
coupled goat anti-mouse IgG was used to stain for the N–P
complexes in the biopsies.
Infection of T-lymphoma cell lines by MV and virus release
All infections performed by rMeGFPV were derived from a virus
stock of 106 PFU/ml. The T-lymphoma cell lines, SeAx, HUT78, and
MyLa2059, were infected with rMeGFPV at various MOI as
indicated for each experiment and incubated at 371C with 5%
CO2. Released viruses were collected from infected cultures at
various time points. Titers were determined by standard plaque
assays.
MV replication and CTCL lysis
MyLa2059 cells were infected with rMeGFPV at MOIs of 0.01, 0.1,
1.0, 5.0, and 10.0 PFU/cell. In order to monitor the effect of serial
virus applications, cells were infected with a MOI of 0.5 PFU/cell on
the first day and 24 hours later with another 0.5 PFU/cell resulting in
the same final MOI (1.0 PFU/cell) administered as in the single-dose
experiment. The cells were monitored daily for GFP expression and
the percentage of infected cells was estimated by two independent
researches by microscopy using the FITC or UV channel filter. To
determine virus replication and cell lysis, 104 cells were infected
with rMeGFPV at an MOI of 5 PFU/cell in a total volume of 1.15 ml
(in duplicates). Infected cells were incubated up to 7 days at 371C
with 5% CO2. Cells and media were harvested separately on days
1–4, and 7. Virus shed into the medium was analyzed by plaque
assays in serial dilutions, and replication of virus within infected
cells was determined by analysis of the viral protein contents at
various days of infection. Protein analysis was performed by
SDS–PAGE and Western blots of cell lysates. Viral proteins were
detected using antibodies directed against N, P (1:1000), and H
(1:250). The time course of cell death was scored when expression of
eGFP was not detectable anymore, indicative of cell lysis.
Tumor grafts and tumor treatment in mice
Outbreed ICR nu/nu mice (purchased from Harlan, Zeist, The
Netherlands) were transplanted with MyLa2059 tumors from donor
mice as described previously (Thaler et al., 2004). Tumor sizes were
calculated according to the equation: lengthwidth height. Nude
mice with a mean tumor volume of 0.22 cm3 were injected i.t. with
3.0 104 PFU MV/dose (n¼ 6) or i.p. with 5.0 104 PFU MV/dose
(n¼ 6) on days 1, 2, 3, and alternate days up to day 15. As a control,
six mice were injected with NaCl i.t. (n¼ 2), or NaCl i.p. (n¼ 2)
using the same volume and the same injection schedule, or left
untreated (n¼ 2). After day 15, the injection schedule for the i.p.
2530 Journal of Investigative Dermatology (2006), Volume 126
V Ku¨nzi et al.
Measles Virus in Cutaneous T-Cell Lymphoma
group was changed to i.t. injections administering 3.0 104 PFU
MV/dose on days 1, 2, 3, and alternate days up to day 15. All animal
studies were approved by the authors’ respective Institutional Board.
Biopsies
Tumor biopsies for histological evaluation were taken following six
i.t. injections of rMV in order to detect histological changes induced
by virus spread. All biopsy specimens were snap-frozen.
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